Spyre Therapeutics, Inc. (SYRE)
103.98
+1.07
(+1.04%)
USD |
NASDAQ |
Nov 13, 16:00
103.98
0.00 (0.00%)
After-Hours: 19:59
Spyre Therapeutics Enterprise Value : 8.332B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 8.332B |
| November 11, 2026 | 8.683B |
| November 10, 2026 | 8.473B |
| November 09, 2026 | 8.880B |
| November 06, 2026 | 8.417B |
| November 05, 2026 | 7.763B |
| November 04, 2026 | 7.984B |
| November 03, 2026 | 8.004B |
| November 02, 2026 | 7.666B |
| October 30, 2026 | 7.760B |
| October 29, 2026 | 7.976B |
| October 28, 2026 | 8.047B |
| October 27, 2026 | 7.984B |
| October 26, 2026 | 7.432B |
| October 23, 2026 | 7.200B |
| October 22, 2026 | 7.380B |
| October 21, 2026 | 7.436B |
| October 20, 2026 | 7.296B |
| October 19, 2026 | 6.695B |
| October 16, 2026 | 6.262B |
| October 15, 2026 | 6.280B |
| October 14, 2026 | 6.148B |
| October 13, 2026 | 6.311B |
| October 12, 2026 | 6.802B |
| October 09, 2026 | 6.783B |
| Date | Value |
|---|---|
| October 08, 2026 | 6.262B |
| October 07, 2026 | 6.347B |
| October 06, 2026 | 6.281B |
| October 05, 2026 | 7.415B |
| October 02, 2026 | 7.457B |
| October 01, 2026 | 7.164B |
| September 30, 2026 | 7.083B |
| September 29, 2026 | 6.462B |
| September 28, 2026 | 6.556B |
| September 25, 2026 | 6.547B |
| September 24, 2026 | 6.671B |
| September 23, 2026 | 6.766B |
| September 22, 2026 | 7.100B |
| September 21, 2026 | 7.106B |
| September 18, 2026 | 6.949B |
| September 17, 2026 | 7.163B |
| September 16, 2026 | 7.030B |
| September 15, 2026 | 7.011B |
| September 14, 2026 | 6.997B |
| September 11, 2026 | 6.980B |
| September 10, 2026 | 6.813B |
| September 09, 2026 | 6.656B |
| September 08, 2026 | 6.996B |
| September 04, 2026 | 6.837B |
| September 03, 2026 | 6.685B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 590.62B |
| Incyte Corp. | 21.01B |
| SELLAS Life Sciences Group, Inc. | 1.484B |
| Relay Therapeutics, Inc. | 3.147B |
| ACADIA Pharmaceuticals, Inc. | 2.230B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -96.12M |
| Total Expenses (Quarterly) | 96.12M |
| EPS Diluted (Quarterly) | -1.087 |
| Earnings Yield | -2.97% |
| Normalized Earnings Yield | -2.587 |